In-depth analysis shows synergy between erlotinib and miR-34a - Wikidata - awgldk - TriplyDB

In-depth analysis shows synergy between erlotinib and miR-34a

In-depth analysis shows synergy between erlotinib and miR-34a

http://www.wikidata.org/entity/Q28539851

about

Non-coding RNAs in lung cancer MicroRNA dysregulation in uveal melanoma: a new player enters the game Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.Assay of lapatinib in murine models of cigarette smoke carcinogenesis.The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis.miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.The orphan nuclear receptor NR4A2 is part of a p53-microRNA-34 network.The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.Technological advances in precision medicine and drug development.Challenges and opportunities of microRNAs in lymphomas.Mir-34: a new weapon against cancer?miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.Non-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatment.miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met.Role of microRNA in metabolic shift during heart failure.MicroRNA-targeted therapeutics for lung cancer treatment.Associations of mRNA:microRNA for the Shared Downstream Molecules of EGFR and Alternative Tyrosine Kinase Receptors in Non-small Cell Lung Cancer.MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines.In vitro Antiproliferative and Apoptosis Inducing Effect of Allium atroviolaceum Bulb Extract on Breast, Cervical, and Liver Cancer Cells.Cytotoxicity and Proapoptotic Effects of Allium atroviolaceum Flower Extract by Modulating Cell Cycle Arrest and Caspase-Dependent and p53-Independent Pathway in Breast Cancer Cell Lines.MicroRNAs in Cancer: challenges and opportunities in early detection, disease monitoring, and therapeutic agents.MicroRNA-34a expression is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma.

P2860

Q26866521-3722F7C6-4314-46C8-9926-AC57235B59CA Q27026746-D83D3273-3C7A-4A49-871E-66C6BF42596F Q33437383-4BCF173D-161E-4E65-B25C-9F90D44BE346 Q34260243-F0215698-04BD-446A-9F0F-E915EC531B33 Q35760211-633BCE34-2812-43B5-8AC1-478B66FA06E5 Q36093612-2163C866-671F-4A83-B2DD-F7EC23914720 Q36189311-987240AA-CCF3-435F-B123-77D9DD1099EC Q36845699-891331FF-B295-449C-BF60-8A9CFE8D9026 Q37041036-74C6004B-A9B5-4761-BEB3-E246AE09847B Q37244501-CD2EA33B-4730-4528-B6A2-BB6C1C40815D Q38251994-A61631C5-97C6-43EA-A4E3-1EAA8FA4DC3B Q38253374-C9946D0B-65CA-44FA-AF7D-96102A0D2E91 Q38366731-CE3E96AC-296A-4E48-B1E8-0645CF168F7B Q38373911-B9CE4459-A708-4B7F-94ED-F59D5B217E68 Q38886375-75BA1592-7105-4591-9A68-924A64490FE4 Q38981243-53D7F9A0-8297-469A-A7DE-4C2C19D9D822 Q39014580-B2349144-12F6-4A51-8C28-221945E2F4FD Q41444378-70AFC462-D45D-41BE-AA3C-7191BC52C30B Q42090153-C27346B2-5A94-47DB-BEC7-4D6B4706FB11 Q42325997-17583231-1A7B-46C2-B85A-791C7B2817FD Q47130606-AF22AE43-4BE7-444B-A980-ABD7DC78B848 Q47920632-D4E16D03-1316-430B-8965-C0BD17BADD18 Q53642072-A1A62812-0EF8-4CA3-A0D6-2D7F4CCDBBE3

P2860

In-depth analysis shows synergy between erlotinib and miR-34a

http://www.wikidata.org/entity/Q28539851

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

In-depth analysis shows synergy between erlotinib and miR-34a

@ast

In-depth analysis shows synergy between erlotinib and miR-34a

@en

In-depth analysis shows synergy between erlotinib and miR-34a

@nl

type

label

In-depth analysis shows synergy between erlotinib and miR-34a

@ast

In-depth analysis shows synergy between erlotinib and miR-34a

@en

In-depth analysis shows synergy between erlotinib and miR-34a

@nl

prefLabel

In-depth analysis shows synergy between erlotinib and miR-34a

@ast

In-depth analysis shows synergy between erlotinib and miR-34a

@en

In-depth analysis shows synergy between erlotinib and miR-34a

@nl

P1433

Q28539851-0B2DC9D5-2CA6-4580-ADC4-F42BDD3A2479

P1476

Q28539851-31BAAB96-0995-44F6-A4BC-DF6CA05ADA0C

P2093

Q28539851-365CB822-E4EF-4CC7-8D9E-04F0098A0847

Q28539851-D205DC2F-E271-4312-9117-1AEA71B02393

Q28539851-E3C1EC6B-54DE-4405-816C-121556A4AF72

P2860

Q28539851-02D4803F-B770-4179-B8D5-7A34BEF37629

Q28539851-03F20564-53C1-4C8D-A9F0-355AF52723E6

Q28539851-08A0C103-993B-4E79-8AA9-F54D2D14DD35

Q28539851-0E47E9C8-8E6A-4FC2-85FF-1AA0BB330994

Q28539851-17FCBDBB-4924-458E-9964-C1E3688CB9BB

Q28539851-192692A7-05CA-4277-827C-097C1B10F6E0

Q28539851-1A1B8282-E4FE-4C6B-B382-914350EED820

Q28539851-1E03B5F7-6A34-4109-8122-EDC2B086F987

Q28539851-239B272A-196D-4E10-8684-33615800367E

Q28539851-23B1509B-F03D-4543-AB1B-297C1DE15FEF

P304

Q28539851-595F2C09-3F73-4894-B587-8D43AD50AF1D

P31

Q28539851-16693D9E-C401-467E-B19A-A18C3848789B

P3181

Q28539851-0931F616-E085-4146-A71D-5B9389C490CD

P356

Q28539851-4E9347DB-5E96-4D7D-9629-95D3091E3533

P407

Q28539851-6998EEF4-3603-457C-861B-D46030613FE9

P433

Q28539851-384272E3-DA6F-4E55-A5AF-4388E8675E9F

P478

Q28539851-27AE35EC-6E27-4DDF-8C65-FEBC715FC0F3

P577

Q28539851-0C233B0F-7AE1-46D6-BB3C-3518430DA9A8

P5875

Q28539851-2E56A78E-8F5A-4C62-B092-14DED0E53BC3

P698

Q28539851-D5CD929D-8FBE-487D-A915-8A57BCE56234

P932

Q28539851-06D65F88-E879-4B4A-9A01-821247755845

P3181

P356

JOURNAL.PONE.0089105

P1433

P1476

In-depth analysis shows synergy between erlotinib and miR-34a

@en

P2093

Andreas G Bader

http://www.w3.org/2001/XMLSchema#string

Jane Zhao

http://www.w3.org/2001/XMLSchema#string

Kevin Kelnar

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

A microRNA component of the p53 tumour suppressor network

High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)

Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling

P304

e89105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2027350

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0089105

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260254827

http://www.w3.org/2001/XMLSchema#string

P698

24551227

http://www.w3.org/2001/XMLSchema#string

P932

3925231

http://www.w3.org/2001/XMLSchema#string